
Additional Names: Sodium polyhydroxyaluminum monocarbonate hexitol complex; aluminum sodium carbonate hexitol complex
Trademarks: Actal (SKB)
Literature References: Description and antacid properties: J. R. Gwilt et al., J. Pharm. Pharmacol. 10, 770 (1958). Stabilization with a hexitol (sorbitol or mannitol): Alford, US 2999790 (1962 to Sterling Drug). Neutralizing capacity: R. E. Barry, J. Ford, Br. Med. J. 1, 413 (1978).
CAS Name: 4-Amino-2-hydroxybenzoic acid phenyl ester
Additional Names: p-aminosalicylic acid phenyl ester; phenyl p-aminosalicylic acid; p-aminosalol; fenamisal
Trademarks: Phenyl PAS; Pheny...
Literature References: Description of properties: Meyer, Antibiot. Annu. 1957-1958, 614. Prepd by Raney nickel reduction of the corresp nitro ester in ethyl acetate: Friere, US 2604488 (1952 to Rhône-Poulenc).
CAS Name: 4-Cyclohexyl-3-ethyl-4H-1,2,4-triazole
Additional Names: 3-ethyl-4-cyclohexyl-4H-1,2,4-triazole; Azoman; Triazol IngelheimPercent Composition: C 67.00%, H 9.56%, N 23.44%
Literature References: Description: Behrens et al., Klin. Wochenschr. 16, 944 (1937).
CAS Name: 2,2-Diethyl-4-pentenamide
Additional Names: diethylallylacetamide
Trademarks: Novonal (Hoechst)
Percent Composition: C 69.63%, H 11.04%, N 9.02%, O 10.31%
Literature References: Description: Bockmühl, Schaumann, Dtsch. Med. Wochenschr. 54, 270 (1928). Pharmacokinetics and metabolism: H. Uehleke, M. Brinkschulte-Freitas, Arch. Pharmacol. 302, 11 (1978). TLC determn in urine: E. Klug, P. Toffel, Arzneim.-Forsch. 29, 1651 (1979).
CAS Name: (2-Ethyl-3-benzofuranyl) (4-hydroxy-3,5-diiodophenyl) methanone
Additional Names: 2-ethyl-3-(3',5'-diiodo-4'-hydroxybenzoyl)benzofuran; 2-ethyl-3-(3',5'-diiodo-4'-hydroxybenzoyl)oxain...
Literature References: Description: Charlier, Acta Cardiol. Suppl. 7, 1-60 (1959). Synthesis: Beaudet, Henaux, BE 553621; GB 836272 (1957, 1960, both to Labaz); Buu-Hoi, Beaudet, US 3012042 (1961 to Soc. Belge Azote Prod. Chim. Marly). Clinical trial in hyperuricemia in renal transplant patients: F. Perez-Ruiz et al., Nephrol. Dial. Transplant. 18, 603 (2003).
CAS Name: N-[(Butylamino)carbonyl]-4-methylbenzenesulfonamide
Additional Names: 1-butyl-3-(p-tolylsulfonyl)urea; tolylsulfonylbutylurea; 3-(p-tolyl-4-sulfonyl)-1-butylurea; N-n-butyl-N'-tosylur...
Literature References: Description: Ehrhart, Naturwissenschaften 43, 93 (1956). Prepn: GB 808071; Aumüller, Herr, DE 1066575 (both 1959 to Hoechst); Ruschig et al., US 2968158 (1961 to Upjohn). Comprehensive description: W. F. Beyer, E. H. Jensen, Anal. Profiles Drug Subs. 3, 513-543 (1974).
CAS Name: 4-Pyridinecarboxylic acid [(2-carboxy-3,4-dimethoxyphenyl)methylene]hydrazide
Additional Names: 5,6-dimethoxyphthalaldehydic acid isonicotinoylhydrazone; 1-(2-carboxy-3,4-dimethoxyben...
Literature References: Description: G. N. Pershin, S.A. Vichkanova, C.A. 51, 10747e (1957); C.A. 52, 1485-1486 (1958); V. A. Buskina, C.A. 54, 744f (1960). Bioavailability: A. F. Zaeko, V. G. Perkova, Farmatsiya (Moscow) 28, 28 (1979), C.A. 92, 185805g (1980). Toxicity study: R. A. Akhundov, Mater. Nauchn. Konf. Azgosmedinstituta 1975, 137, C.A. 86, 50678y (1977).
CAS Name: 4-Amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester monohydrochloride
Additional Names: 2-chloro-4-aminobenzoic acid diethylaminoethyl ester hydrochloride
Trademarks: Nesacain...
Literature References: Description: Hädicke, Pharm. Zentralhalle 94, 384 (1955).
CAS Name: 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acidPercent Composition: C 64.78%, H 4.73%, F 8.91%, N 6.57%, O 1...
Literature References: Des-F(6)-quinolone antibacterial; topoisomerase II inhibitor. Prepn: Y. Todo et al., WO 9729102; eidem, US 6025370 (1997, 2000 both to Toyama); and antibacterial activity: K. Hayashi et al., Arzneim.-Forsch. 52, 903 (2002). HPLC determn in serum: D. Xuan et al., J. Chromatogr. B 765, 37 (2001). Mechanism of action study: D. Ince et al., Antimicrob. Agents Chemother. 46, 3370 (2002). Comparative antimicrobial spectra: M. Takahata et al., ibid. 43, 1077 (1999); M. Bassetti et al., ibid. 46, 234 (2002). Clinical pharmacokinetics: D. A. Gajjar et al., ibid. 47, 2256 (2003); and pharmacodynamics: S. Van Wart et al., ibid. 48, 4766 (2004). Toxicology study: A. Nagai et al., J. Toxicol. Sci. 27, 219 (2002). Review of pharmacology and therapeutic potential: R. Frechette, Curr. Opin. Invest. Drugs 2, 1706-1711 (2001).
CAS Name: 1,7-Dihydro-6H-purin-6-one
Additional Names: purin-6(1H)-one; sarcine; sarkin
Percent Composition: C 44.12%, H 2.96%, N 41.16%, O 11.75%
Literature References: Desmotropic forms: purin-6-ol; 1H-purin-6-ol; 3H-purin-6-ol; 9H-purin-6-ol; purin-6(3H)-one; 9H-purin-6(1H)-one. Formed in the animal body during the breakdown of nucleic acids; formation from adenosine continues after death. Also widely distributed in the vegetable kingdom. Numerous syntheses, e.g., from 2,6,8-trichloropurine: Fischer, Ber. 30, 2226 (1897); by oxidation of adenine: Krüger, Z. Physiol. Chem. 18, 445 (1894). By reduction of uric acid: Sundwik, ibid. 76, 486 (1912); by condensing ethyl cyanoacetate and thiourea in the presence of Na-ethoxide: Traube, Ann. 331, 64 (1904); from mercapto-4-hydroxy-6-aminopyrimidine: Taylor, Cheng. J. Org. Chem. 25, 148 (1960). Reviews: Levene, Bass, ACS Monograph Series no. 56, entitled "Nucleic Acids" (New York, 1931); Chargaff, Davidson, Nucleic Acids vols. I II (Academic Press, New York, 1955).
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
